LY231514 500mg/m2 and LY231514 1000mg/m2 in patients with advanced non-small cell lung cancer who were previously treated with prior systemic anti cancer therapy: a randomized phase II trial

Trial Profile

LY231514 500mg/m2 and LY231514 1000mg/m2 in patients with advanced non-small cell lung cancer who were previously treated with prior systemic anti cancer therapy: a randomized phase II trial

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
    • 27 Dec 2007 The expected completion date for this trial is now 1 Dec 2008 according to ClinicalTrials.gov.
    • 23 Sep 2007 Survival outcomes were reported at ECCO 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top